Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Ritsuko Iwanaga to Humans

This is a "connection" page, showing publications Ritsuko Iwanaga has written about Humans.

 
Connection Strength
 
 
 
0.141
 
  1. Iwanaga R, Yamamoto TM, Gomez K, Nguyen LL, Woodruff ER, Post MD, Mikeska RG, Danis E, Danhorn T, Boorgula MP, Mitra SS, Marjon NA, Bitler BG, Brubaker LW. Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. Cancer Res Commun. 2024 08 01; 4(8):1919-1932.
    View in: PubMed
    Score: 0.024
  2. Iwanaga R, Truong BT, Hsu JY, Lambert KA, Vyas R, Orlicky D, Shellman YG, Tan AC, Ceol C, Artinger KB. Loss of prdm1a accelerates melanoma onset and progression. Mol Carcinog. 2020 09; 59(9):1052-1063.
    View in: PubMed
    Score: 0.018
  3. Iwanaga R, Orlicky DJ, Arnett J, Guess MK, Hurt KJ, Connell KA. Comparative histology of mouse, rat, and human pelvic ligaments. Int Urogynecol J. 2016 Nov; 27(11):1697-1704.
    View in: PubMed
    Score: 0.013
  4. Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012 Jul 05; 14(4):R100.
    View in: PubMed
    Score: 0.010
  5. Nakajima R, Zhou Y, Shirasawa M, Nishimura N, Zhao L, Fikriyanti M, Kamiya Y, Iwanaga R, Bradford AP, Shinmyozu K, Nishibuchi G, Nakayama JI, Kurayoshi K, Araki K, Ohtani K. DEAD/H Box 5 (DDX5) Augments E2F1-Induced Cell Death Independent of the Tumor Suppressor p53. Int J Mol Sci. 2024 Dec 10; 25(24).
    View in: PubMed
    Score: 0.006
  6. Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner. Mol Cancer Res. 2024 12 03; 22(12):1117-1127.
    View in: PubMed
    Score: 0.006
  7. Iwanaga R, Komori H, Ohtani K. Differential regulation of expression of the mammalian DNA repair genes by growth stimulation. Oncogene. 2004 Nov 11; 23(53):8581-90.
    View in: PubMed
    Score: 0.006
  8. Zhao L, Nakajima R, Zhou Y, Shirasawa M, Fikriyanti M, Kamiya Y, Toh H, Komori H, Iwanaga R, Bradford AP, Nishitani H, Kurayoshi K, Araki K, Ohtani K. The N-Terminal Region of the Transcription Factor E2F1 Contains a Novel Transactivation Domain and Recruits General Transcription Factor GTF2H2. Biomolecules. 2024 Oct 25; 14(11).
    View in: PubMed
    Score: 0.006
  9. Shirasawa M, Nakajima R, Zhou Y, Zhao L, Fikriyanti M, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani K. Activation of the CDK7 Gene, Coding for the Catalytic Subunit of the Cyclin-Dependent Kinase (CDK)-Activating Kinase (CAK) and General Transcription Factor II H, by the Trans-Activator Protein Tax of Human T-Cell Leukemia Virus Type-1. Genes (Basel). 2024 Aug 15; 15(8).
    View in: PubMed
    Score: 0.006
  10. Hayati RF, Nakajima R, Zhou Y, Shirasawa M, Zhao L, Fikriyanti M, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani K. Trans-Activation of the Coactivator-Associated Arginine Methyltransferase 1 (Carm1) Gene by the Oncogene Product Tax of Human T-Cell Leukemia Virus Type 1. Genes (Basel). 2024 May 27; 15(6).
    View in: PubMed
    Score: 0.006
  11. Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023 Apr-May; 27(4-5):361-371.
    View in: PubMed
    Score: 0.005
  12. Nakajima R, Deguchi R, Komori H, Zhao L, Zhou Y, Shirasawa M, Angelina A, Goto Y, Tohjo F, Nakahashi K, Nakata K, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani K. The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F. Biochem Biophys Res Commun. 2023 06 30; 663:154-162.
    View in: PubMed
    Score: 0.005
  13. Komori H, Goto Y, Kurayoshi K, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani K. Differential requirement for dimerization partner DP between E2F-dependent activation of tumor suppressor and growth-related genes. Sci Rep. 2018 05 31; 8(1):8438.
    View in: PubMed
    Score: 0.004
  14. Kurayoshi K, Shiromoto A, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani K. Ectopic expression of the CDK inhibitor p21Cip1 enhances deregulated E2F activity and increases cancer cell-specific cytotoxic gene expression mediated by the ARF tumor suppressor promoter. Biochem Biophys Res Commun. 2017 01 29; 483(1):107-114.
    View in: PubMed
    Score: 0.003
  15. Kurayoshi K, Okuno J, Ozono E, Iwanaga R, Bradford AP, Kugawa K, Araki K, Ohtani K. The phosphatidyl inositol 3 kinase pathway does not suppress activation of the ARF and BIM genes by deregulated E2F1 activity. Biochem Biophys Res Commun. 2017 Jan 22; 482(4):784-790.
    View in: PubMed
    Score: 0.003
  16. Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. Breast Cancer Res. 2014 Oct 30; 16(5):462.
    View in: PubMed
    Score: 0.003
  17. Kurayoshi K, Ozono E, Iwanaga R, Bradford AP, Komori H, Ohtani K. Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):240-6.
    View in: PubMed
    Score: 0.003
  18. Ozono E, Komori H, Iwanaga R, Tanaka T, Sakae T, Kitamura H, Yamaoka S, Ohtani K. Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts. Genes Cells. 2012 Aug; 17(8):660-72.
    View in: PubMed
    Score: 0.003
  19. Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):451-7.
    View in: PubMed
    Score: 0.002
  20. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest. 2009 Sep; 119(9):2663-77.
    View in: PubMed
    Score: 0.002
  21. Ozono E, Komori H, Iwanaga R, Ikeda MA, Iseki S, Ohtani K. E2F-like elements in p27(Kip1) promoter specifically sense deregulated E2F activity. Genes Cells. 2009 Jan; 14(1):89-99.
    View in: PubMed
    Score: 0.002
  22. Komori H, Enomoto M, Nakamura M, Iwanaga R, Ohtani K. Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. EMBO J. 2005 Nov 02; 24(21):3724-36.
    View in: PubMed
    Score: 0.002
  23. Matsumura-Arioka Y, Ohtani K, Hara T, Iwanaga R, Nakamura M. Identification of two distinct elements mediating activation of telomerase (hTERT) gene expression in association with cell growth in human T cells. Int Immunol. 2005 Feb; 17(2):207-15.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)